CN111733287A - Kit for detecting pathogenic nucleic acid of fever with thrombocytopenia syndrome - Google Patents
Kit for detecting pathogenic nucleic acid of fever with thrombocytopenia syndrome Download PDFInfo
- Publication number
- CN111733287A CN111733287A CN202010573257.1A CN202010573257A CN111733287A CN 111733287 A CN111733287 A CN 111733287A CN 202010573257 A CN202010573257 A CN 202010573257A CN 111733287 A CN111733287 A CN 111733287A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- kit
- fever
- detecting
- thrombocytopenia syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 56
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 55
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 55
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 37
- 206010037660 Pyrexia Diseases 0.000 title claims abstract description 30
- 206010043554 thrombocytopenia Diseases 0.000 title claims abstract description 30
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 29
- 238000001514 detection method Methods 0.000 claims abstract description 35
- 239000000523 sample Substances 0.000 claims abstract description 28
- 239000002773 nucleotide Substances 0.000 claims abstract description 20
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 20
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 14
- 230000004544 DNA amplification Effects 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 101710163270 Nuclease Proteins 0.000 claims abstract description 9
- 238000012197 amplification kit Methods 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 244000052769 pathogen Species 0.000 abstract description 25
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 231100000676 disease causative agent Toxicity 0.000 description 5
- 239000013642 negative control Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 108700004991 Cas12a Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241001535172 Severe fever with thrombocytopenia virus Species 0.000 description 1
- 101800005109 Triakontatetraneuropeptide Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000012271 agricultural production Methods 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- NMEHNETUFHBYEG-IHKSMFQHSA-N tttn Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 NMEHNETUFHBYEG-IHKSMFQHSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kit for detecting pathogenic nucleic acid of fever with thrombocytopenia syndrome, which comprises: crRNA-1, LbCas12a nuclease for detecting pathogenic nucleic acid of fever with thrombocytopenia syndrome, nucleic acid detection probe, first upstream primer, first downstream primer,
DNA Amplification kit, water and 1 × NEbufferTM2.1; the nucleic acid detection probe is IAB-TTATT-BHQ-1; the nucleotide sequence of the first upstream primer is shown as SEQ ID NO. 3; the nucleotide sequence of the first downstream primer is shown as SEQ ID NO. 4. The kit of the invention canThe kit can quickly and accurately detect the SFTS pathogen nucleic acid, and has the advantages of good detection specificity, high sensitivity, realization of high-sensitivity detection at room temperature, and convenient and quick operation.
Description
Technical Field
The invention belongs to the technical field of molecular biology. More particularly, it relates to a kit for detecting nucleic acids of pathogens of the fever with thrombocytopenia syndrome (SFTS).
Background
The main clinical manifestations of fever with thrombocytopenia syndrome (SFTS) pathogen infected persons are fever, digestive tract symptoms, thrombocytopenia, leukopenia, liver and kidney function damage, and bleeding manifestations of some infected persons. The disease mainly occurs in hills and mountainous areas, and patients mainly take adult farmers who engage in agricultural production, and part of the patients are bitten by ticks. The usual diagnostic methods are often based on empirical judgment or detection of individual pathogens, and products based on the global detection of common pathogens of syndrome are rare. In order to realize the early detection of SFTSV, it is very important to develop a diagnostic method for accurately, efficiently and quickly detecting the pathogen of SFTS with low cost.
At present, in the detection of pathogens with fever accompanied by thrombocytopenia (SFTS), the gold standard is still a Real-time fluorescence quantitative PCR (RT-PCR) detection technology, and the sensitivity and the specificity are higher. Real-time fluorescence PCR detection alone, which generally takes about two hours, is used. The whole detection process also comprises the steps of sampling, processing samples and the like, and the total time is usually more than two hours. The method has the main disadvantages that the detection takes long time, and the PCR detection needs to depend on a PCR instrument or an expensive real-time quantitative PCR instrument and other various matched equipment.
Therefore, a highly sensitive kit that does not require expensive equipment, is low cost, and can rapidly and accurately generate fever with thrombocytopenia syndrome (SFTS) pathogenic viruses is highly desired.
Disclosure of Invention
The object of the present invention is to overcome the disadvantages of the prior art and to provide crRNA-1 for detecting the nucleic acid of the causative agent of fever with thrombocytopenia syndrome.
It is a second object of the present invention to provide crRNA-2 for detecting nucleic acids of pathogens of fever with thrombocytopenia syndrome.
It is a third object of the present invention to provide a kit for detecting nucleic acids of pathogens of fever with thrombocytopenia syndrome.
It is a fourth object of the present invention to provide a second kit for detecting a nucleic acid of a causative agent of fever with thrombocytopenia syndrome.
The technical scheme of the invention is summarized as follows:
the method is used for detecting the crRNA-1 of the pathogenic nucleic acid of the fever with thrombocytopenia syndrome, and the nucleotide sequence of the crRNA-1 is shown as SEQ ID NO. 1.
Detecting the crRNA-2 of the pathogenic nucleic acid of the fever with thrombocytopenia syndrome, wherein the nucleotide sequence of the crRNA-2 is shown as SEQ ID NO. 2.
The first kit for detecting the pathogenic nucleic acid of the fever with thrombocytopenia syndrome comprises crRNA-1, LbCas12a nuclease for detecting the pathogenic nucleic acid of the fever with thrombocytopenia syndrome, a nucleic acid detection probe, a first upstream primer, a first downstream primer, a second upstream primer and a second downstream primer,
DNA Amplification kit, water and 1 × NEbufferTM2.1；
The nucleic acid detection probe is IAB-TTATT-BHQ-1;
the nucleotide sequence of the first upstream primer is shown as SEQ ID NO. 3;
the nucleotide sequence of the first downstream primer is shown as SEQ ID NO. 4;
the second kit for detecting the pathogenic nucleic acid of the fever with thrombocytopenia syndrome comprises crRNA-2, LbCas12a nuclease, a nucleic acid detection probe, a second upstream primer, a second downstream primer and a second primer for detecting the pathogenic nucleic acid of the fever with thrombocytopenia syndrome,
DNA Amplification kit, water and 1 × NEbufferTM2.1；
The nucleic acid detection probe is IAB-TTATT-BHQ-1;
the nucleotide sequence of the second upstream primer is shown as SEQ ID NO. 5;
the nucleotide sequence of the second downstream primer is shown as SEQ ID NO. 6;
the invention has the advantages that:
the kit for detecting the pathogen nucleic acid of the fever with thrombocytopenia syndrome (SFTS) can quickly and accurately detect the pathogen nucleic acid of the SFTS, and has the advantages of good detection specificity, high sensitivity, realization of high-sensitivity detection at room temperature, and convenient and quick operation.
Drawings
FIG. 1 is a graph showing the results of detection of SFTS pathogen nucleic acid L fragments mock samples (plasmids) using the kit of example 2.
FIG. 2 is a graph showing the results of detection of SFTS pathogen nucleic acid L fragments mock samples (plasmids) using the kit of example 3.
Detailed Description
The present invention will be further illustrated by the following specific examples.
Example 1
Crrnas were designed to detect the nucleic acid of the causative agent of fever with thrombocytopenia syndrome (SFTS).
Acquiring a genome sequence of the SFTS pathogen, and searching a specific identification region of the SFTS pathogen through bioinformatics analysis and alignment.
The specific operation steps are as follows, searching the whole genome sequence of the existing SFTS pathogen HB-29 in the laboratory in the NCBI nucleic acid sequence library to obtain the whole genome sequence. Sequences of "TTTN" were searched for within the HB-29 whole genome sequence and used as an alternative database for crRNA targeting sequences.
According to the screening principle, parameters such as GC content, base uniformity, sequence conservation and the like of a sequence are obtained, a target site recognition sequence with the size of 20-24nt is finally obtained, then a direct repetitive sequence with the size of 20-21nt is added with the obtained target site recognition sequence with the size of 20-24nt to obtain the crRNA for detecting SFTS pathogen nucleic acid, 2 crRNA-1 and crRNA-2 are obtained in total, the nucleotide sequence of the crRNA-1 is shown as SEQ ID NO.1, and the nucleotide sequence of the crRNA-2 is shown as SEQ ID NO. 2.
Example 2
A kit for detecting a nucleic acid of a causative agent of fever with thrombocytopenia syndrome (SFTS), comprising: crRNA-1, LbCas12a nuclease for detection of SFTS pathogen nucleic acids (
Lba Cas12a (Cpf1), BioLabs), nucleic acid detection probe, first upstream primer, first downstream primer, and,
DNA Amplification kit (commercially available), water (DEPC-treated water) and 1 × NEbufferTM2.1(BioLabs)；
The nucleic acid detection probe is IAB-TTATT-BHQ-1 (manufactured by consignment of biological companies);
the nucleotide sequence of the first upstream primer is shown as SEQ ID NO. 3;
the nucleotide sequence of the first downstream primer is shown as SEQ ID NO. 4.
Example 3
A second kit for detecting a nucleic acid of a causative agent of fever with thrombocytopenia syndrome (SFTS), comprising: crRNA-2, LbCas12a nuclease for detection of SFTS pathogen nucleic acids (
Lba Cas12a (Cpf1), BioLabs), nucleic acid detection probe, second forward primer, second reverse primer, and,
DNA Amplification kit (commercially available), water (DEPC-treated water) and 1 × NEbufferTM2.1(BioLabs)；
The nucleic acid detection probe is IAB-TTATT-BHQ-1 (manufactured by consignment of biological companies);
the nucleotide sequence of the second upstream primer is shown as SEQ ID NO. 5;
the nucleotide sequence of the second downstream primer is shown as SEQ ID NO. 6.
Example 4
Use of the kit of example 2:
(1) 2.4uL of the first forward primer aqueous solution with a concentration of 10. mu.M, 2.4uL of the first downstream primer aqueous solution with a concentration of 10. mu.M, and 4uL of the first forward primer aqueous solution with a concentration of 1.8X10-5ng/uL detection of the simulated sample (SFTS pathogen nucleic acid L fragment genome nucleotide sequence shown in SEQ ID NO.7, GENBANK)The gene sequence number is: KP202165.1) to
In the DNA Amplification mixing System: (
The DNA Amplification mixing system is
Preparing each component of the kit of DNA Amplification according to the instruction), and amplifying for 20min at 39 ℃;
(2) 1uL LbCas12a nuclease, 3uL1 × NEbufferTM2.1 and 4uL of crRNA-1 aqueous solution with the concentration of 1 mu M for detecting SFTS pathogen nucleic acid are incubated, and the temperature is 25 ℃ for 10 min;
(3) mixing 20uL of the amplification product obtained in the step (1) and 8uL of the incubation product obtained in the step (2) in a 384-well plate, and then adding 2uL of an aqueous solution of a nucleic acid detecting probe at a concentration of 1. mu.M. The reaction system is placed in a multifunctional microplate reader, the reaction is carried out for 20min at 37 ℃, and the fluorescence value is taken for result interpretation.
And (3) judging effective results: after removing background fluorescence of the sample, the sample is defined as positive when the fluorescence value is more than or equal to 3 times of that of the negative control sample, and the sample is defined as negative when the fluorescence value is less than 3 times of that of the negative control sample. See fig. 1.
FIG. 1 is a graph showing the results of detection of SFTS pathogen nucleic acid L fragments mock samples (plasmids) using the kit of example 2.
Example 5
Use of the kit of example 3:
(1) 2.4uL of the second forward primer aqueous solution with a concentration of 10. mu.M, 2.4uL of the second reverse primer aqueous solution with a concentration of 10. mu.M, and 4uL of the second forward primer aqueous solution with a concentration of 1.8X10-5ng/uL detection simulation sample water solution (SFTS pathogen nucleic acid L fragment genome nucleotide sequence is shown in SEQ ID NO.7, GENBANK gene sequence number is KP202165.1)
In the DNA Amplification mixing System: (
The DNA Amplification mixing system is
Preparing each component of the kit of DNA Amplification according to the instruction), and amplifying for 20min at 39 ℃;
(2) 1uL LbCas12a nuclease, 3uL1 × NEbufferTM2.1 and 4uL of crRNA-2 aqueous solution with the concentration of 1 mu M for detecting SFTS pathogen nucleic acid are incubated, and the temperature is 25 ℃ for 10 min;
(3) mixing 20uL of the amplification product obtained in the step (1) and 8uL of the incubation product obtained in the step (2) in a 384-well plate, and then adding 2uL of an aqueous solution of a nucleic acid detecting probe at a concentration of 1. mu.M. The reaction system is placed in a multifunctional microplate reader, the reaction is carried out for 20min at 37 ℃, and the fluorescence value is taken for result interpretation.
And (3) judging effective results: after removing background fluorescence of the sample, the sample is defined as positive when the fluorescence value is more than or equal to 3 times of that of the negative control sample, and the sample is defined as negative when the fluorescence value is less than 3 times of that of the negative control sample. See fig. 2.
FIG. 2 is a graph showing the results of detection of SFTS pathogen nucleic acid L fragments mock samples (plasmids) using the kit of example 3.
Sequence listing
<110> Tianjin university
<120> kit for detecting nucleic acid of pathogenic agent of fever with thrombocytopenia syndrome
<160>7
<170>SIPOSequenceListing 1.0
<210>1
<211>45
<212>RNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
uaauuucuac uaaguguaga uagaauuggg gaauguuccc uccac 45
<210>2
<211>45
<212>RNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
uaauuucuac uaaguguaga ugaaaaguug cuuguagcuu ucaug 45
<210>3
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
gcttgaggct attagtaggg ca 22
<210>4
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
tctattgatc tctagccgct cc 22
<210>5
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>5
gtgtcctgaa agagattggg ac 22
<210>6
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>6
gtaccacata acccccttct ca 22
<210>7
<211>6368
<212>DNA
<213> genus phlebovirus of bunyaviridae (The genus Banyangvrus in family familypheniuiviridae)
<400>7
acacagagac gcccagatga acttggaagt gctttgtggt aggataaacg tggagaatgg 60
gctgtctctt ggagaaccag gcctgtacga ccaaatctac gataggccag ggcttccaga 120
cctagatgtg actgtcgatg ccactggtgt tacagtggac ataggggctg tgccagactc 180
agcatcacaa ttgggctcat caatcaacgc tgggttgatc acaatccagc tctcagaggc 240
atataagatc aatcatgact tcacgttttc tggcctgtca aagacaacag accgacgcct 300
ctcagaggta ttccccatta cccatgatgg ttctgatggg atgacccctg atgtgattca 360
cacaagattg gatggaacca ttgtggtggt tgaattttca accactagga gccataacat 420
tgggggcctg gaggcagcat ataggacaaa gatagaaaaa tatagggacc caatctcaag 480
acgtgttgat atcatggaga acccgagggt cttctttggc gtaattgtag tctcgtcagg 540
aggggttctg tccaacatgc ccctgactca ggatgaggca gaggagctca tgtacaggtt 600
ctgcatagcc aatgagatct acactaaggc tagatctatg gatgcagaca ttgagctaca 660
gaagagtgaa gaagagcttg aggctattag tagggcacta tcattcttca gtctgtttga 720
gcctaacatt gaaagagtgg agggaacatt ccccaattct gaaatcgaga tgctggaaca 780
gtttctctca acaccagctg atgttgactt catcaccaag accctcaaag caaaagaggt 840
agaggcctat gctgatcttt gcgacagtca ctacctaaag cctgagaaaa ctattcagga 900
gcggctagag atcaatagat gtgaggctat agacaaaact caggacctac tagctggcct 960
gcatgcgagg agcaacaagc aaacatcatt gaatcgaggg acagtcaaac tcccaccctg 1020
gctaccaaag ccatcaagtg aatcaataga catcaagacc gactcaggct ttggttcttt 1080
gatggatcat ggcgcatatg gtgagctgtg ggcaaagtgc cttctagatg tctcactggg 1140
caatgtggag ggggtagtca gtgaccctgc aaaagagctt gacattgcta tctctgatga 1200
tccagaaaaa gataccccca aagaggcaaa gataacctat aggcgattca agcctgcctt 1260
aagttcaagt gcccgtcaag aattttctct ccaaggagtg gaggggaaga aatggaagag 1320
aatggcagca aaccagaaga aagagaagga gtcccatgag acattgagcc ctttcttgga 1380
tgttgaagac attggagatt tcctaacatt caacaatctt cttgctgatt cgaggtatgg 1440
agatgagtcc gtccaaagag ctgtgtcaat cttgttggaa aaggcatctg ccatgcaaga 1500
cacagagctt actcatgccc tcaatgactc atttaagagg aacctaagca gtaatgtggt 1560
ccagtggtct ctttgggtct cctgcttagc acaggagcta gctagtgccc tgaagcagca 1620
ctgcagggct ggtgagttca tcatcaagaa gctgaagttc tggcctatct atgtcattat 1680
caagccgacc aaatcatcat cccatatctt cttcagcttg gggatccgca aggctgacgt 1740
gacaaggagg ctaactggca gggtcttctc tgacaccatt gatgctgggg aatgggagct 1800
aacagagttc aaaagcctaa agacatgcaa gctcacaaat cttgtcaacc tgccatgcac 1860
catgctgaac tcaatagctt tctggagaga gaagttgggc gtggccccat ggctggttcg 1920
aaagccttgt tcagagctca gagagcaggt gggcctgacc ttcctggtca gtctggagga 1980
caagtccaag actgaggaga tcatcacctt gacaaggtac acccagatgg agggctttgt 2040
ctccccccct atgctgccta agccccaaaa gatgctaggg aaactggatg gacctttgag 2100
aactaagcta caggtatacc tcctcaggaa acatctggat tgcatggtgc gaattgcttc 2160
tcagccattc aacttaatcc ctagggaggg gagggtagag tggggaggaa cattccatgc 2220
catctcaggc cggtccacaa accttgagaa tatggtgaac agctggtaca ttgggtacta 2280
caagaacaaa gaggagtcaa cagagctaaa tgccctcgga gaaatgtaca agaagattgt 2340
ggagatggaa gaggacaagc ccagtagccc tgagtttcta gggtggggag acacagactc 2400
ccctaagaag catgaattct cacggagctt cctcagagct gcttgctcat ctctggagag 2460
agaaattgct cagcggcatg gaagacaatg gaagcagaac cttgaggagc gtgtcctgaa 2520
agagattggg accaagaaca tcctggacct tgcatccatg aaagctacaa gcaacttttc 2580
caaagattgg gagctctact cagaagtcca gaccaaagag taccataggt ccaaactgct 2640
ggagaagatg gccacattga ttgagaaggg ggttatgtgg tacattgatg ctgtgggcca 2700
ggcatggaag gcagttctgg atgacgggtg catgcgaatc tgtctcttca aaaagaatca 2760
gcatggtggc ctcagagaga tctacgttat ggatgctaat gcccggcttg tgcagtttgg 2820
ggtcgagacc atggccaggt gtgtctgtga gctaagccca catgagactg ttgccaaccc 2880
taggctcaag aattctatca tagagaacca tgggctgaag tcagcccgca gtcttggccc 2940
tggctctatt aacataaact catccaatga tgccaagaag tggaatcagg ggcactacac 3000
aacaaagcta gctctagttc tttgttggtt catgccagcc aaattccaca gattcatttg 3060
ggctgccatt tccatgtttc ggagaaaaaa gatgatggtg gacctaaggt ttttggctca 3120
cctcagtact aaatctgagt ctaggtcatc tgatccgttc agggaagcaa tgacagacgc 3180
cttccatggt aatagggaag tttcatggat ggacaaaggg cgaacttaca taaagacaga 3240
gacaggaatg atgcagggca tactgcactt tacatctagc ctcctccact cttgtgttca 3300
gagcttctac aagtcctatt tcgtctcgaa gctcaaggag ggctacatgg gggaaagcat 3360
cagtggggtg gtggatgtca tagaaggctc tgacgactca gcgatcatga tcagcatacg 3420
ccccaagtca gacatggatg aagtccgatc aaggttcttt gttgctaact tgctccactc 3480
tgtcaagttc ttgaaccctt tgtttgggat ttattcttca gagaaatcaa cagtgaacac 3540
agtgtattgt gtcgagtata actctgaatt ccatttccac aggcacttgg ttagacccac 3600
actgagatgg atagcagcgt ctcaccaaat ctcagagaca gaagcccttg caagcaggca 3660
agaagattac tccaaccttc taacgcagtg cttggaagga ggggcctcat tctctcttac 3720
ctacctcata cagtgcgctc agctcctgca ccactacatg cttctaggac tatgcttaca 3780
tcccttattt ggaaccttca tggggatgtt gatatcagac ccagatccag ccctagggtt 3840
cttcctcatg gacaaccctg cattcgcagg gggtgcagga tttagattca atctgtggag 3900
agcctgcaag actacagacc ttggacggaa gtatgcttat tattttaatg agatacaggg 3960
taaaacaaag ggagatgagg actacagagc tctggatgcc acatcgggag gaactctcag 4020
ccactctgtt atggtgtatt ggggggacag gaagaagtat caggctttgt tgaacaggat 4080
gggccttcct gaggactggg tagagcagat agatgagaat cctggagtcc tttacaggag 4140
agctgccaac aagaaggaac tactcttaaa actggcagag aaggttcatt ctcctggtgt 4200
aactagcagc ctgagtaagg ggcatgtggt gcctcgggtg gtggcagcag gagtatacct 4260
tctctcacgc cactgctttc gctttagctc aagcattcat ggcaggggct cagcacagaa 4320
ggctagcctt ataaaactgc taatgatgtc ttctgtttct gccatgaagc acgggggctc 4380
actaaaccct aatcaggagc gaatgctctt ccctcaggct caagagtatg acagagtatg 4440
cacattgctt gaggaagttg aacacctaac agggaaattt gttgttaggg agagaaacat 4500
tgtcaggagc cgcatagact tgttccaaga accagtggac ttgcggtgca aggcagagga 4560
tctggtgtca gaggtgtggt ttggcctgaa aaggactaag cttggacccc gtctcctcaa 4620
ggaagagtgg gacaaactta gggcttcatt tgcatggctg agcacagacc catctgaaac 4680
actgagggat ggtccttttc ttagccatgt gcagtttagg aacttcatag cccacgttga 4740
tgccaaatca agatcagtca ggctcctggg tgcccccgtg aagaagtcag gtggggtcac 4800
caccataagc caagtagtta gaatgaactt cttccctggt tttagcctag aagctgagaa 4860
gagcttagat aatcaggaaa gacttgagag catctccatc ctcaagcatg tcttgttcat 4920
ggtcttgaat ggcccataca ctgaggagta caagctggag atgatcatag aggccttctc 4980
tactcttgtg ataccacagc catcagaggt catcaggaaa tctaggacca tgaccttatg 5040
cctcttatcg aattacttgt ctagtaaggg tgggtccatt ctagaccaga ttgagagggc 5100
acagtcagga actctaggag gctttagcaa gccccagaag acattcatta ggccaggagg 5160
tggtgttggc tataagggaa aaggtgtgtg gactggggtg atggaggaca cccatgttca 5220
aattctgata gatggagatg ggactagtaa ctggcttgag gagatcaggc tcagtagtga 5280
tgccaggctt tatgatgtca ttgaatccat ccgaaggtta tgtgatgacc ttgggatcaa 5340
caacagggtg gcatctgcat atagaggtca ttgcatggtt aggctgagtg gattcaagat 5400
caagccagca tcaaggactg acgggtgtcc agtcaggatc atggaaaggg gcttcaggat 5460
tagggaactt caaaatccgg atgaggtcaa gatgagagtg aggggcgaca tcctcaacct 5520
ctctgtcaca atacaagaag gaagggtcat gaacattctg agctacaggc caagagacac 5580
tgatatatca gagtcagctg cagcatacct ctggagtaat cgagacctct tctcctttgg 5640
gaagaaggaa ccatcctgca gctggatctg cttaaaaact cttgacaatt gggcctggtc 5700
acatgcctca gttctcctgg caaatgatag gaagacccaa ggcattgaca atagagctat 5760
ggggaacatt ttcagggact gtcttgaagg ttctcttaga aagcaagggc tgatgaggtc 5820
aaagctcaca gagatggtgg agaagaatgt agttccttta acaactcaag agctcgtcga 5880
catcctggag gaggacattg acttttcaga tgtcatagct gtggagctct cagaggggtc 5940
gcttgacatt gaatccatct ttgatggggc acctatcttg tggtctgctg aggtggaaga 6000
gtttggagaa ggagtggtgg ctgtgagcta ttccagtaag tactatcatc taaccctgat 6060
ggaccaagct gccatcacaa tgtgtgcgat catgggtaag gaaggctgta gagggcttct 6120
taccgagaag agatgcatgg cagccatacg agagcaggta cggccattcc tcatattcct 6180
gcaaatacct gaggacagca tttcttgggt gtctgatcag ttctgcgact ccaggggcct 6240
tgatgaagag agcaccatta tgtggggtta actttgaaac acggttggaa cgcagttgat 6300
gtgtctgtgg gtggctaggg agtgttggtt ttagaaggat ttccttaaga tctgggcggt 6360
ctttgtgt 6368
Claims (4)
1. The crRNA-1 for detecting the nucleic acid of the pathogenic agent of the fever with thrombocytopenia syndrome is characterized by being shown as SEQ ID NO. 1.
2. The crRNA-2 for detecting the nucleic acid of the pathogenic agent of the fever with thrombocytopenia syndrome is characterized by being shown as SEQ ID NO. 2.
3. The kit for detecting the nucleic acid of the pathogenic agent of the fever with thrombocytopenia syndrome is characterized by comprising: crRNA-1, LbCas12a nuclease for detecting pathogenic nucleic acid of fever with thrombocytopenia syndrome, nucleic acid detection probe, first upstream primer, first downstream primer,
DNA Amplification kit, water and 1 × NEbufferTM2.1；
The nucleic acid detection probe is IAB-TTATT-BHQ-1;
the nucleotide sequence of the first upstream primer is shown as SEQ ID NO. 3;
the nucleotide sequence of the first downstream primer is shown as SEQ ID NO. 4.
4. The kit for detecting the nucleic acid of the pathogenic agent of the fever with thrombocytopenia syndrome is characterized by comprising: crRNA-2, LbCas12a nuclease for detecting pathogenic nucleic acid of fever with thrombocytopenia syndrome, a nucleic acid detection probe, a second upstream primer, a second downstream primer,
DNA Amplification kit, water and 1 × NEbufferTM2.1；
The nucleic acid detection probe is IAB-TTATT-BHQ-1;
the nucleotide sequence of the second upstream primer is shown as SEQ ID NO. 5;
the nucleotide sequence of the second downstream primer is shown as SEQ ID NO. 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010573257.1A CN111733287B (en) | 2020-06-22 | 2020-06-22 | Kit for detecting pathogenic nucleic acid of fever with thrombocytopenia syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010573257.1A CN111733287B (en) | 2020-06-22 | 2020-06-22 | Kit for detecting pathogenic nucleic acid of fever with thrombocytopenia syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111733287A true CN111733287A (en) | 2020-10-02 |
| CN111733287B CN111733287B (en) | 2022-10-11 |
Family
ID=72650316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010573257.1A Expired - Fee Related CN111733287B (en) | 2020-06-22 | 2020-06-22 | Kit for detecting pathogenic nucleic acid of fever with thrombocytopenia syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111733287B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113755646A (en) * | 2021-10-09 | 2021-12-07 | 安徽医科大学第四附属医院 | CrRNA and CRISPR-Cas12a system for novel bunyavirus detection and application |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105154585A (en) * | 2015-07-14 | 2015-12-16 | 江苏省疾病预防控制中心 | Isothermal amplification reagent kit for detecting fever and thrombocytopenia syndrome viruses and application of isothermal amplification reagent kit |
| WO2019011022A1 (en) * | 2017-07-14 | 2019-01-17 | 上海吐露港生物科技有限公司 | Application of cas protein, method for detecting target nucleic acid molecule and kit |
| US20190144929A1 (en) * | 2017-03-15 | 2019-05-16 | The Broad Institute, Inc. | Devices for crispr effector system based diagnostics |
| CN111077310A (en) * | 2019-12-04 | 2020-04-28 | 天津大学 | Enzyme linked immunosorbent assay kit for detecting fever with thrombocytopenia syndrome virus antigen |
| CN111108220A (en) * | 2017-03-15 | 2020-05-05 | 博德研究所 | CRISPR-Effector System-based diagnostics for Virus detection |
| CN111254223A (en) * | 2020-03-21 | 2020-06-09 | 上海海关动植物与食品检验检疫技术中心 | Reaction system and kit for detecting African swine fever virus nucleic acid and application of reaction system and kit |
-
2020
- 2020-06-22 CN CN202010573257.1A patent/CN111733287B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105154585A (en) * | 2015-07-14 | 2015-12-16 | 江苏省疾病预防控制中心 | Isothermal amplification reagent kit for detecting fever and thrombocytopenia syndrome viruses and application of isothermal amplification reagent kit |
| US20190144929A1 (en) * | 2017-03-15 | 2019-05-16 | The Broad Institute, Inc. | Devices for crispr effector system based diagnostics |
| CN111108220A (en) * | 2017-03-15 | 2020-05-05 | 博德研究所 | CRISPR-Effector System-based diagnostics for Virus detection |
| WO2019011022A1 (en) * | 2017-07-14 | 2019-01-17 | 上海吐露港生物科技有限公司 | Application of cas protein, method for detecting target nucleic acid molecule and kit |
| CN111077310A (en) * | 2019-12-04 | 2020-04-28 | 天津大学 | Enzyme linked immunosorbent assay kit for detecting fever with thrombocytopenia syndrome virus antigen |
| CN111254223A (en) * | 2020-03-21 | 2020-06-09 | 上海海关动植物与食品检验检疫技术中心 | Reaction system and kit for detecting African swine fever virus nucleic acid and application of reaction system and kit |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113755646A (en) * | 2021-10-09 | 2021-12-07 | 安徽医科大学第四附属医院 | CrRNA and CRISPR-Cas12a system for novel bunyavirus detection and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111733287B (en) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106947838B (en) | African swine fever virus non-structural gene real-time fluorescence LAMP (loop-mediated isothermal amplification) detection primer group, kit and detection method | |
| CN106906306B (en) | Rapid and sensitive genotype identification and nucleic acid detection | |
| JP2013536678A (en) | Quantification of residual host cell DNA by real-time quantitative PCR | |
| CN107988326A (en) | Prawn Acute Hepatic pancreatic necrosis（AHPND）RAA constant temperature fluorescence detection method and reagent | |
| CN111705163A (en) | Novel coronavirus rapid detection kit based on thermal convection PCR | |
| CN105018485A (en) | Primer and probe for detecting peste des petits ruminants virus by virtue of RPA (Recombinase Polymerase Amplification) technique | |
| CN113718045A (en) | DNA fragment, primer, probe and kit for detecting 4 kinds of Bordetella pertussis and specifically detecting Bordetella pertussis and application | |
| CN112410472A (en) | Primer probe combination and detection kit for detecting mycoplasma pneumoniae, chlamydia pneumoniae and adenovirus | |
| CN110669870A (en) | Real-time fluorescent quantitative RT-PCR (reverse transcription-polymerase chain reaction) detection primer, probe and detection kit for serotype of Palima serogroup virus | |
| CN111286559A (en) | Primer, probe and kit for detecting African swine fever virus | |
| CN111733287B (en) | Kit for detecting pathogenic nucleic acid of fever with thrombocytopenia syndrome | |
| CN114058738A (en) | Fluorescence quantitative PCR detection kit for detecting eriocheir sinensis reovirus | |
| CN110257556B (en) | Nucleic acid detection kit for pathogenic pathogen of sexually transmitted diseases | |
| CN113528704A (en) | Primer group, probe, kit and detection method for rapidly identifying novel coronavirus | |
| CN113481326B (en) | Isothermal nucleic acid amplification reaction reagent, isothermal nucleic acid amplification method and application thereof | |
| CN111455106B (en) | Kit for detecting 2019 novel coronavirus nucleic acid | |
| CN116219040A (en) | Molecular marker, primer probe group and detection method for detecting lactobacillus plantarum S58 | |
| CN111500774B (en) | Epidemic hemorrhagic disease virus and serotype identification RT-PCR kit | |
| CN111424074B (en) | Nucleic acid detection kit for quantifying trace residue of mouse source tissue | |
| CN114438259B (en) | SGLV and YEZV dual fluorescent quantitative RT-PCR nucleic acid group, kit and method for synchronous detection | |
| CN117965800B (en) | Compositions and kits for QPCR-based detection of Aspergillus fumigatus, yersinia pneumoconica and Cryptococcus neoformans | |
| CN110205361B (en) | RT-qsCPA primer for detecting vibrio parahaemolyticus as well as kit and method thereof | |
| CN112301104B (en) | RDA method and kit for rapidly detecting chlamydia trachomatis | |
| CN107227378A (en) | Detect the RPA IAC primers and method of vibrio mimicus | |
| KR102111038B1 (en) | Primer set for diagnosing severe fever with thrombocytopenia syndrome virus infection, kit and method for diagnosing comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20221011 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |